Giangrande P H, Kimbrel E A, Edwards D P, McDonnell D P
Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Mol Cell Biol. 2000 May;20(9):3102-15. doi: 10.1128/MCB.20.9.3102-3115.2000.
The human progesterone receptor (PR) exists as two functionally distinct isoforms, hPRA and hPRB. hPRB functions as a transcriptional activator in most cell and promoter contexts, while hPRA is transcriptionally inactive and functions as a strong ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity. Although the precise mechanism of hPRA-mediated transrepression is not fully understood, an inhibitory domain (ID) within human PR, which is necessary for transrepression by hPRA, has been identified. Interestingly, although ID is present within both hPR isoforms, it is functionally active only in the context of hPRA, suggesting that the two receptors adopt distinct conformations within the cell which allow hPRA to interact with a set of cofactors that are different from those recognized by hPRB. In support of this hypothesis, we identified, using phage display technology, hPRA-selective peptides which differentially modulate hPRA and hPRB transcriptional activity. Furthermore, using a combination of in vitro and in vivo methodologies, we demonstrate that the two receptors exhibit different cofactor interactions. Specifically, it was determined that hPRA has a higher affinity for the corepressor SMRT than hPRB and that this interaction is facilitated by ID. Interestingly, inhibition of SMRT activity, by either a dominant negative mutant (C'SMRT) or histone deacetylase inhibitors, reverses hPRA-mediated transrepression but does not convert hPRA to a transcriptional activator. Together, these data indicate that the ability of hPRA to transrepress steroid hormone receptor transcriptional activity and its inability to activate progesterone-responsive promoters occur by distinct mechanisms. To this effect, we observed that hPRA, unlike hPRB, was unable to efficiently recruit the transcriptional coactivators GRIP1 and SRC-1 upon agonist binding. Thus, although both receptors contain sequences within their ligand-binding domains known to be required for coactivator binding, the ability of PR to interact with cofactors in a productive manner is regulated by sequences contained within the amino terminus of the receptors. We propose, therefore, that hPRA is transcriptionally inactive due to its inability to efficiently recruit coactivators. Furthermore, our experiments indicate that hPRA interacts efficiently with the corepressor SMRT and that this activity permits it to function as a transdominant repressor.
人孕酮受体(PR)以两种功能不同的亚型hPRA和hPRB形式存在。在大多数细胞和启动子环境中,hPRB作为转录激活因子发挥作用,而hPRA转录无活性,并作为类固醇激素受体转录活性的强配体依赖性反式显性阻遏物发挥作用。尽管hPRA介导的反式阻遏的确切机制尚未完全阐明,但已确定人PR中的一个抑制域(ID)是hPRA反式阻遏所必需的。有趣的是,尽管ID存在于两种hPR亚型中,但它仅在hPRA的背景下具有功能活性,这表明这两种受体在细胞内采取不同的构象,使得hPRA能够与一组不同于hPRB所识别的辅因子相互作用。为支持这一假设,我们利用噬菌体展示技术鉴定了差异调节hPRA和hPRB转录活性的hPRA选择性肽。此外,通过体外和体内方法的结合,我们证明这两种受体表现出不同的辅因子相互作用。具体而言,已确定hPRA对共抑制因子SMRT的亲和力高于hPRB,并且这种相互作用由ID促进。有趣的是,通过显性负突变体(C'SMRT)或组蛋白去乙酰化酶抑制剂抑制SMRT活性,可逆转hPRA介导的反式阻遏,但不会将hPRA转化为转录激活因子。总之,这些数据表明hPRA反式阻遏类固醇激素受体转录活性的能力及其激活孕酮反应性启动子的无能是通过不同机制发生的。为此,我们观察到与hPRB不同,hPRA在激动剂结合后无法有效募集转录共激活因子GRIP1和SRC-1。因此,尽管两种受体在其配体结合域内都含有已知共激活因子结合所需的序列,但PR与辅因子以有效方式相互作用的能力受受体氨基末端所含序列的调节。因此,我们提出hPRA由于其无法有效募集共激活因子而转录无活性。此外,我们的实验表明hPRA与共抑制因子SMRT有效相互作用,并且这种活性使其能够作为反式显性阻遏物发挥作用。